期刊文献+

Ⅱ型表皮生长因子受体(HER2/neu)过度表达的种族差异:子宫浆液性乳头状癌的主要预后指标 被引量:2

Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu):A major prognostic indicator in uterine serous papillary cancer
下载PDF
导出
摘要 Objective: A difference in survival rates between black and white patients with cancer of the corpus uteri is well established. This study was conducted to determine whether the overexpression of HER2/neu oncogene is associated with poor outcome in uterine serous papillary endometrial cancer, which is a highly aggressive variant of endometrial cancer, and whether a racial difference in the frequency of HER2/neu overexpression may contribute to the disparity in endometrial cancer survival. Study design: Immunohistochemical evaluation was used to examine HER2/neu expression in paraffin blocks from 27 women with stage IA to IV uterine serous papillary endometrial cancer. Univariable analysis was performed and followed by multivariable analysis with Cox’ s proportional hazard model to evaluate whether HER2/neu expression was associated with poor outcome in uterine serous papillary endometrial cancer. Results: Black patients tended to be younger (P =. 02) and have higher HER2/neu expression than white patients (trend P =. 02). Seven of 10 black patients (70% ) showed heavy (3+ ) expression, compared with 4 of 17 white patients (24% ; P =. 04). The association of heavy HER2/neu expression with race persisted after age was controlled through stratification (P =. 05). Earlier deaths from uterine serous papillary endometrial cancer were seen among heavy HER2/neu expressers (P =. 002), black patients (P =. 04), and patients ≤ 65 years old (P =. 04). However, multivariate Cox regression showed that short survival was associated significantly with heavy HER2/neu expression (P =. 02) but not with age (P =. 07) or race (P =. 35), which indicates that HER2/neu expression accounted for much of the race disparity in survival in this patient population. Conclusion: Overexpression of HER2/neu in uterine serous papillary endometrial cancer is an independent variable that is associated with poor outcome, occurs more frequently in black women, and may contribute to racial disparity in survival. HER2/neu expression may guide clinic Objective: A difference in survival rates between black and white patients with cancer of the corpus uteri is well established. This study was conducted to determine whether the overexpression of HER2/neu oncogene is associated with poor outcome in uterine serous papillary endometrial cancer, which is a highly aggressive variant of endometrial cancer, and whether a racial difference in the frequency of HER2/neu overexpression may contribute to the disparity in endometrial cancer survival. Study design: Immunohistochemical evaluation was used to examine HER2/neu expression in paraffin blocks from 27 women with stage IA to IV uterine serous papillary endometrial cancer. Univariable analysis was performed and followed by multivariable analysis with Cox' s proportional hazard model to evaluate whether HER2/neu expression was associated with poor outcome in uterine serous papillary endometrial cancer. Results: Black patients tended to be younger (P =. 02) and have higher HER2/neu expression than white patients (trend P =. 02). Seven of 10 black patients (70% ) showed heavy (3+ ) expression, compared with 4 of 17 white patients (24% ; P =. 04). The association of heavy HER2/neu expression with race persisted after age was controlled through stratification (P =. 05). Earlier deaths from uterine serous papillary endometrial cancer were seen among heavy HER2/neu expressers (P =. 002), black patients (P =. 04), and patients ≤ 65 years old (P =. 04). However, multivariate Cox regression showed that short survival was associated significantly with heavy HER2/neu expression (P =. 02) but not with age (P =. 07) or race (P =. 35), which indicates that HER2/neu expression accounted for much of the race disparity in survival in this patient population. Conclusion: Overexpression of HER2/neu in uterine serous papillary endometrial cancer is an independent variable that is associated with poor outcome, occurs more frequently in black women, and may contribute to racial disparity in survival. HER2/neu expression may guide clinical
出处 《世界核心医学期刊文摘(妇产科学分册)》 2005年第7期13-14,共2页 Core Journal in Obstetrics/Gynecology
  • 相关文献

同被引文献7

  • 1杨婉华,王常玉,王世宣,卢运萍,朱涛,马丁.重组人红细胞生成素在恶性肿瘤贫血中的应用[J].中国妇产科临床杂志,2002,3(2):81-84. 被引量:4
  • 2肖志华,汤昊,柯玉华,蒋晖,于丁.重组人红细胞生成素治疗肿瘤化疗所致贫血的临床观察[J].临床肿瘤学杂志,2005,10(2):193-194. 被引量:6
  • 3Rizzo JD, Lichtin AE, Woolf SH, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American society of clinical oncology and the american society of hematology[ J ]. Blood ,2002,100 (7) :2303-2320. 被引量:1
  • 4Mantovani G, Ghiani M, Gurreki L, et al. Assessment of the efficancy of two dosages and schedules of human recombinant erythropoietin in the prevention and COlTection and con'ection of cisplation induced anemia in cancer patients[J]. Oncol Rep,1999,6(2) :421-426. 被引量:1
  • 5Olsson AM, Svensson JH, Sundstrom J, et al. Erythropoietin treatment in metastatic breast cancer-effects on Hb,quality of life and need for transfusion[J]. Acta Oncol,2002,41 (6) :517-524. 被引量:1
  • 6Jones-Burton C, Seliger SL. Racial variations in erythropoietic response to epoetin alfa in chronic kidney disease and the impact of smoking[J]. Nephrol Dial Transplant,2005,20(12) :2739-2745. 被引量:1
  • 7《乳腺癌HER2检测指南(2019版)》编写组,杨文涛,步宏.《乳腺癌HER2检测指南(2019版)》[J].中华病理学杂志,2019,48(3):169-175. 被引量:267

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部